Volume 30, Issue 4 (Avicenna Journal of Clinical Medicine-Winter 2024)                   Avicenna J Clin Med 2024, 30(4): 194-201 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khazaei M, Valdbeighi M, Khazaei S, Mirmoeini E A, Mehri F. Investigation of the Effectiveness of Doxycycline on the Improvement of Oxidative Stress Biomarkers in Patients with Ischemic Stroke. Avicenna J Clin Med 2024; 30 (4) :194-201
URL: http://sjh.umsha.ac.ir/article-1-2865-en.html
1- Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- General Practitioner, Hamadan University of Medical Sciences, Hamadan, Iran
3- Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
4- Occupational Health and Safety Research Center& Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
5- Nutritional Health Research Center & Occupational Health and Safety Research Center, Hamadan University of Medical Sciences, Hamadan, Iran , freshteh_mehri@yahoo.com
Abstract:   (176 Views)
Background and Objective: Considering the role of oxidative stress in the pathogenesis of ischemic stroke, antioxidant and anti-inflammatory drugs can be a potential treatment in these patients. This study aimed to investigate the effectiveness of doxycycline on the improvement of oxidative stress biomarkers in patients with ischemic stroke.
Materials and Methods: This clinical trial study was performed on 48 patients with ischemic stroke who had referred to Besat Hospital in Hamadan, Iran, in 2023. They were randomly and equally assigned to the intervention (doxycycline at the rate of 100 mg every 12 hours) and placebo groups for one week. Before and after the intervention, serum levels of malondialdehyde (MDA), glutathione (GSH), total oxidant status, total antioxidant capacity, c-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured.
Results: The study groups had no statistically significant difference in all measured biomarkers in the first 24 h after the stroke (P>0.05). In both study groups, the biomarkers of MDA and total oxidant status decreased after treatment. This decrease was greater in the intervention group, compared to the placebo group with a statistically significant difference. The total antioxidant capacity and GSH increased in both groups, and this increase was more significant in the intervention group, compared to the placebo group. In both groups, serum levels of CRP and ESR decreased, but no statistically significant difference was observed between the two groups.
Conclusion: Addition of doxycycline to the standard treatment of ischemic stroke patients may reduce oxidative stress biomarkers; however, to confirm the results of this study, studies with a larger sample size are needed.
 
Full-Text [PDF 1422 kb]   (84 Downloads)    
Type of Study: Original | Subject: Neurology

References
1. González RG, Hirsch JA, Koroshetz W, Lev MH, Schaefer PW. Acute ischemic stroke. Springer.2011.
2. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, et al. Global stroke statistics. Int J Stroke. 2017;12(1):13-32. PMID: 27794138 DOI: 10.1177/1747493016676285
3. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. Br Med Bull. 2009;92:7-32. PMID: 19776034 DOI: 10.1093/bmb/ldp028
4. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94(9):634-634A. PMID: 27708464 DOI: 10.2471/BLT.16.181636
5. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340(23):1781-7. PMID: 10362821 DOI: 10.1056/NEJM199906103402302
6. Lv W, Xu J, Wang X, Li X, Xu Q, Xin H. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment. ACS Nano. 2018;12(6):5417-26. PMID: 29869497 DOI: 10.1021/acsnano. 8b00477
7. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med. 2005;38(11):1433-44. PMID: 15890617 DOI: 10.1016/j.freeradbiomed.2005.01.019
8. Orellana-Urzúa S, Rojas I, Líbano L, Rodrigo R. Pathophysiology of Ischemic Stroke: Role of Oxidative Stress. Curr Pharm Des. 2020;26(34):4246-60. PMID: 32640953 DOI: 10.2174/1381612826666200708133912
9. Bolaños JP, Moro MA, Lizasoain I, Almeida A. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Adv Drug Deliv Rev. 2009;61(14):1299-315. PMID: 19716390 DOI: 10.1016/j.addr.2009.05.009
10. Kim S, Lee W, Jo H, Sonn SK, Jeong SJ, Seo S, et al. The antioxidant enzyme Peroxiredoxin-1 controls stroke-associated microglia against acute ischemic stroke. Redox Biol. 2022;54:102347. PMID: 35688114 DOI: 10.1016/j.redox.2022.102347
11. Franco C, Ho B, Mulholland D, Hou G, Islam M, Donaldson K, et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am J Pathol. 2006;168(5):1697-709. PMID: 16651635 DOI: 10.2353/ajpath.2006.050613
12. Clemens DL, Duryee MJ, Sarmiento C, Chiou A, McGowan JD, Hunter CD, et al. Novel antioxidant properties of doxycycline. Int J Mol Sci. 2018;19(12):4078. PMID: 30562944 DOI: 10.3390/ijms19124078
13. Pandya R, Mao L, Zhou H, Zhou S, Zeng J, John Popp A, et al. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem. 2011;11(2):81-97. PMID: 21521165 DOI: 10.2174/187152411796011321
14. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239(1):70-6. PMID: 8660627 DOI: 10.1006/abio.1996.0292
15. Lyden P, Zivin J. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5(1):1-16. PMID: 8452759
16. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42(7):1952-5. PMID: 21636813 DOI: 10.1161/STROKEAHA.110.612358
17. Herculano-Houzel S. Scaling of brain metabolism with a fixed energy budget per neuron: implications for neuronal activity, plasticity and evolution. PLoS One. 2011;6(3):e17514. PMID: 21390261 DOI: 10.1371/ journal.pone.0017514.
18. Shirley R, Ord EN, Work LM. Oxidative stress and the use of antioxidants in stroke. Antioxidants (Basel). 2014;3(3):472-501. PMID: 26785066 DOI: 10.3390/antiox3030472
19. Lapchak PA, Zivin JA. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. Stroke. 2003;34(8):2013-8. PMID: 12855833 DOI: 10.1161/01.STR.0000081223.74129.04
20. Yu ZF, Bruce‐Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53(5):613-25. PMID: 9726432 DOI: 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1
21. Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. J Clin Neurosci. 2007;14(11):1062-6. PMID: 17884504 DOI: 10.1016/j.jocn.2006.11.008
22. Clark WM, Lessov N, Lauten JD, Hazel K. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J Mol Neurosci. 1997;9(2):103-8. PMID: 9407391 DOI: 10.1007/BF02736854
23. Reasoner DK, Hindman BJ, Dexter F, Subieta A, Cutkomp J, Smith T. Doxycycline reduces early neurologic impairment after cerebral arterial air embolism in the rabbit. Anesthesiology. 1997;87(3):569-76. PMID: 9316962 DOI: 10.1097/00000542-199709000-00017
24. Fan X, Lo EH, Wang X. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke. 2013;44(3):745-52. PMID: 23422086 DOI: 10.1161/STROKEAHA.111.000309
25. Jiang Y, Zhu J, Wu L, Xu G, Dai J, Liu X. Tetracycline inhibits local inflammation induced by cerebral ischemia via modulating autophagy. PLoS One. 2012;7(11):e48672. PMID: 23144925 DOI: 10.1371/journal.pone.0048672
26. Saeed M, Arun MZ, Guzeloglu M, Onursal C, Gokce G, Korkmaz CG, et al. Low-dose doxycycline inhibits hydrogen peroxide-induced oxidative stress, MMP-2 up-regulation and contractile dysfunction in human saphenous vein grafts. Drug Des Devel Ther. 2019;13:1791-801. PMID: 31213768 DOI: 10.2147/DDDT.S187842
27. Castro JE, Vado-Solis I, Perez-Osorio C, Fredeking TM. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol. 2011;2011:370872. PMID: 21461372 DOI: 10.1155/2011/370872
28. Hannawi Y, Hannawi B, Rao CP, Suarez JI, Bershad EM. Stroke-associated pneumonia: major advances and obstacles. Cerebrovasc Dis. 2013;35(5):430-43. PMID: 23735757 DOI: 10.1159/000350199
29. Cerisano G, Buonamici P, Valenti R, Sciagrà R, Raspanti S, Santini A, et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J. 2014;35(3):184-91. PMID: 24104875 DOI: 10.1093/eurheartj/eht420
30. Nederkoorn PJ, Westendorp WF, Hooijenga IJ, de Haan RJ, Dippel DW, Vermeij FH, et al. Preventive antibiotics in stroke study: rationale and protocol for a randomised trial. Int J Stroke. 2011;6(2):159-63. PMID: 21371281 DOI: 10.1111/j.1747-4949.2010.00555.x

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb